Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery

Published:2024-07-14 Issue:9 Volume:19 Page:1043-1069
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Manen-Freixa Leticia¹^ORCID,Antolin Albert A.¹²^ORCID

Affiliation:

1. Oncobell Division, Bellvitge Biomedical Research Institute (IDIBELL) and ProCURE Department, Catalan Institute of Oncology (ICO), Barcelona, Spain

2. Center for Cancer Drug Discovery, The Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK

Funder

Instituto de Salud Carlos III

Institute of Cancer Research

Generalitat de Catalunya

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2024.2376643

Reference346 articles.

1. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

2. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

3. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

4. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

5. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP